The Protocol:
Separating Longevity Science
from Silicon Valley Cosplay

The Biology of Aging: 12 Hallmarks, One Framework

In 2013, researchers Carlos Lopez-Otin, Maria Blasco, Linda Partridge, Manuel Serrano, and Guido Kroemer published a landmark review in Cell titled "The Hallmarks of Aging." It became the most cited paper in aging biology. The framework identified nine distinct molecular and cellular processes that drive biological aging — each one a potential intervention target. In 2022, the same team updated the list to twelve hallmarks in Cell, incorporating new evidence on inflammation ("inflammaging"), dysbiosis (gut microbiome decline), and compromised autophagy.

The Hallmarks framework matters because it defines what "targeting aging" actually means biologically — and therefore what legitimate longevity interventions are doing when they work. Every credible pharmacological candidate in the longevity pipeline (rapamycin, senolytics, NAD+ precursors, metformin) maps to one or more of these twelve processes.

The $2M Leaderboard Problem

Bryan Johnson created the Rejuvenation Olympics — a public leaderboard tracking biological aging rates across approximately 4,000 participants using epigenetic clock testing (DunedinPACE algorithm). The leaderboard measures how fast each participant is biologically aging per chronological year: a score of 1.0 means you're aging one year biologically for every year chronologically. Below 1.0 means slower biological aging.

Johnson spends $2 million per year on his personal protocol: 50+ daily pills, a team of 30+ physicians, plasma exchange transfusions, continuous biomarker monitoring, and a precisely engineered diet. His DunedinPACE score as of November 2024: 0.69 — ranking him 6th on the leaderboard he created and funds.

Julie Gibson Clark, a 55-year-old working mother in Phoenix, ranked 2nd worldwide. Her protocol: gym membership, a vegetable-rich diet, regular exercise, meditation, and adequate sleep. She spends approximately $27 per month. Johnson's score is better than virtually all of humanity — but Clark's is better than his, at a price ratio of roughly 6,000 to one. The gap is not an argument that expensive interventions are useless; Johnson's detailed self-experimentation data is genuine science. It is an argument that the marginal return on spending past a basic behavioral foundation is sharply diminishing.

What the Blue Zones Actually Show

The five documented Blue Zones — regions with disproportionately high concentrations of centenarians — have been studied since the early 2000s by researcher Dan Buettner in collaboration with National Geographic and scientists from multiple disciplines. Despite spanning three continents and five distinct cultures, all five share an identical foundation: plant-predominant diet, regular low-intensity movement embedded in daily life, managed stress, strong social bonds, and moderate caloric intake. None involve a supplement protocol. None involve a continuous glucose monitor.

The Okinawan longevity advantage has begun measurably eroding in younger generations who adopted Western dietary patterns — a natural experiment that implicates diet and lifestyle directly. Younger Okinawans now have higher obesity rates and lower life expectancy than their grandparents' generation, despite living in the same place with access to the same social structures. The variable that changed was the food.

The Evidence Tiers: Ranked by Quality of Human Data

Every longevity intervention exists somewhere on a spectrum from "replicated in large human populations for decades" to "worked in a petri dish once." The industry does not clearly communicate where on that spectrum any given product sits. The tiers below are based on the quality and consistency of human evidence — not animal data alone, not mechanistic plausibility, not the credibility of the person promoting it.

Tier 1 — Strong Human Evidence

Tier 2 — Promising (Strong Animal Data + Human Mechanistic Evidence)

Tier 3 — Uncertain (Preliminary or Conflicting Human Evidence)

Tier 4 — Hype (Minimal Quality Evidence, Aggressively Marketed)

The Rapamycin Problem: Best Animal Data, Real Human Risk

Rapamycin occupies a unique position in longevity pharmacology: it has the strongest animal lifespan extension data of any drug ever tested, and it has documented real-world human side effects that caused the most prominent self-experimenter to discontinue it after five years. Understanding both sides honestly is the difference between longevity science and marketing.

The funding gap is a structural distortion in longevity pharmacology: the drugs with the strongest animal evidence tend to be off-patent generics. There is no commercial incentive to fund definitive human trials for a $30/month drug. The drugs with the largest commercial incentives are novel compounds under active patent — which have strong marketing budgets and weak evidence bases. The incentive structure of drug development systematically inverts the evidence-to-marketing ratio in this space.

The Epigenetic Clock: How Biological Age Is Actually Measured

The Rejuvenation Olympics leaderboard — and most serious longevity research — uses epigenetic clocks to measure biological age. The concept was introduced by Steve Horvath (UCLA) in 2013: DNA methylation patterns across the genome change predictably with chronological age, enabling a molecular "clock" that can be read from a blood sample. The Horvath clock, GrimAge, and the DunedinPACE algorithm (used by the leaderboard) each measure different aspects of aging rate.

DunedinPACE specifically measures the pace of aging over the preceding year rather than biological age at a snapshot — making it more sensitive to recent intervention effects. A DunedinPACE score of 0.70 means you're aging 0.70 biological years per chronological year. Johnson's score of 0.69 and Clark's score of 0.665 both represent significant deceleration versus population average (1.0). The gap between them represents approximately $167,000 per month in protocol cost for a 0.025 DunedinPACE difference.

The CALERIE Phase 2 trial found that 25% caloric restriction over two years produced measurable improvement in epigenetic age clocks — one of the first direct human demonstrations that a behavioral intervention changes the biological clock reading. This is a meaningful result: not just improved biomarkers, but a change in the molecular aging signal itself.